A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study

NCT07677059 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

264

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma (Diagnosis)

Interventions

DRUG: KT-621

Sponsor

Kymera Therapeutics, Inc.